April 29, 2013 – Isoflux Incorporated, a world leader in advanced surface treatments, announced the hiring of John Lanzafame as CEO. Isoflux founder Dr. David Glocker will assume the role of Chief Technology Officer, and continue to serve on the Board of Directors.
Lanzafame brings over 20 years of experience with customized surface treatments in the medical device industry, including past service as president of STS Biopolymers, Inc. and CEO of Biophan Technologies, Inc.
STS Biopolymers was a world leader in polymer surface treatments for medical devices, including lubricious coatings for catheters and guidewires, and drug eluting coatings for coronary stents. STS licensed their propriety technology to major medical device manufacturers, along with providing coating services and contract research. STS Biopolymers was purchased by Angiotech Pharmaceuticals in 2003.
“Isoflux has a very exciting technology portfolio, and is well positioned for growth,” Lanzafame said. “The business model is similar to what we did at STS, combining technology licensing with contract manufacturing, but Isoflux also adds coating equipment sales so we have a complete line of solutions. The applications for our technology also extend well beyond the medical device industry, so there is tremendous potential.”
“I’m excited to join the Isoflux team.”
Dr. Glocker added, “John’s experience in licensing, business development and coating services will help take Isoflux to the next level. We are very pleased to have him on board.”